search for
or search by
Results 1 - 20 of 424
Vetter to Expand its Secondary Packaging Service Capacity to Meet Rising Demands
Vetter, a global leader in prefilled drug delivery systems and an expert in complex packaging projects, recently announced a major expansion of its secondary packaging capacities as a response to rising customer needs and market demands for complex packaging solutions.
Arcturus Therapeutics Announces Strategic Collaboration With J&J Innovation to Discover & Develop RNA Medicines
Arcturus Therapeutics, Inc. recently announced it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The two companies will work together to develop and commercialize nucleic acid-based drug products for the treatment of Hepatitis B, using Arcturus’ UNA Oligomer chemistry and LUNAR™ lipid-mediated delivery platform.
White Paper: Establishing cGMP Manufacturing Capability for Phase 1 Sterile, Dispersed, Injectable Dosage Forms
As a product transitions from pre-clinical development to a clinical development phase, the manufacturing process takes on a much greater role in the overall success of the project.........
AMRI Launches Stand-Alone Service; Expanding Solutions for Impurity Analysis & Toxicology Risk Assessment
AMRI, a global contract research, development and manufacturing organization that partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will now be offering its impurity solutions as a stand-alone service.
Cambrex Invests in Generic API Development & Manufacturing Capabilities at its Milan Site
Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), recently announced that it has made a number of investments, in both R&D and manufacturing capabilities to support the development and production of generic APIs, at its site in Paullo, Milan, Italy.
Aptar Pharma Showcase its Premium Injectables Portfolio
Aptar Pharma, a leading drug delivery systems provider, will showcase the latest developments in its Premium injectables portfolio when it exhibits at Parenteral Drug Association’s (PDA) Universe of Pre-filled Syringes and Injection Devices in November.
CordenPharma Acquires Pfizer API Manufacturing Facility in Boulder, CO
CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO), has entered into definite agreements to acquire the former Hospira Boulder (Colorado) high containment API site from Pfizer, Inc. The closing of the transaction is anticipated to occur in November 2017.
KemPharm & Genco Sciences Announce Technology Licensing Agreement
KemPharm, Inc., a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, recently announced it has entered into a technology licensing and assignment agreement with Genco Sciences, LLC (Genco).
Achieve Life Science Announces Advancement of Cytisine Clinical Development Program
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, recently announced the commencement of a multi-dose study to evaluate both PK and PD characteristics of cytisine.
Amgen-Backed Immatics Lands $58 Million to Develop T-Cell Receptor-Based Immunotherapies
Immatics, a leading company in the field of cancer immunotherapy, recently announced the completion of its Series E financing, raising $58 million.
American Heart Association's New Scientific Statement Deems the Corus CAD Test Valid & Useful for Clinicians Evaluating Obstructive CAD
CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, recently announced today in a Scientific Statement by the American Heart Association, the Corus® CAD blood test was evaluated and "deemed to be valid and useful" in the workup of patients with suspected coronary artery disease (CAD).
Roivant Sciences Launches Datavant to Improve Clinical Trials With Artificial Intelligence
Roivant Sciences recently announced the launch of Datavant, a new company focused on employing artificial intelligence to improve the clinical trial process.
Catalent to Acquire Cook Pharmica for $950 Million
Catalent, Inc., the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, recently announced it has reached an agreement to acquire Bloomington, Indiana-based Cook Pharmica LLC, an integrated provider of drug substance and drug product manufacturing and related services.
DFB Pharmaceuticals Forms NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform
DFB Pharmaceuticals, a privately held investment and development group in Ft. Worth, TX, has taken on this challenge by forming NanOlogy, in collaboration with CritiTech and US Biotest, to finance and develop a breakthrough technology platform for producing unique, patented, naked nanoparticles of paclitaxel and docetaxel.
APAC Drug Delivery Devices Market to Reach $5.4 Billion in 2023​
Drug delivery devices market in Asia Pacific (India, China, Japan, South Korea, Australia, New Zealand, and Taiwan) region is expected to grow at CAGR 3.9%, from $4.1 billion in 2016 to $5.4 billion in 2023, according GlobalData, a recognized leader in providing business information and analytics.
CordenPharma Inaugurates Third Development Suite for Highly Potent Oral Solid Dosage
CordenPharma is pleased to announce the completion of its newest early development suite for Highly Potent, oral solid dosage products in CordenPharma Plankstadt (DE). The new facility allows for the production of small batches, from 100g to approximately 1000g.
AMRI Expands Sterile Production Capacity
AMRI, a global contract research, development and manufacturing organization, is expanding its sterile manufacturing capacity. The addition of an aseptic pre-filled syringe filling line at our manufacturing facility in Albuquerque, N.M., adds capacity to manufacture roughly 50 million syringes per year.
GSK Exercises Option Over Adaptimmune’s SPEAR T-Cell Therapy Program
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, recently announced that GlaxoSmithKline plc has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program.
Novartis AG Receives First Ever FDA Approval for CAR-T
A new era in cancer treatment is now here. The US FDA recently gave the nod to Switzerland-based Novartis AG for its gene therapy cancer treatment, a first in the US.
Huber Closes $630-Million Sale of Silica Business to Evonik
The J.M. Huber Corporation has completed the sale of the Silica business unit of Huber Engineered Materials (HEM) to Evonik Industries AG, a global specialty chemicals company. The $630-million transaction, completed after approvals from the European Commission and other global regulatory bodies, transfers ownership of the HEM Silica facilities in North America, Europe and Asia to Evonik.


Click here to see the showcases

BIO Investor Forum
October 17-18, 2017
The Westin St. Francis, San Francisco, CA US
Partnership Opportunities in Drug Delivery (PODD)
October 19-20
Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Vienna, Austria

November 12-17
San Diego, CA

Pre-Filled Syringes Europe
January 17-18, 2018
Copthorne Tara Hotel, London UK

Drug Delivery Partnerships
January 22-24 Palm Beach, FL

3rd Annual Drug Development Networking Summit
March 8, 2018  Hilton Hotel Parsippany NJ
PDA Annual Meeting
March 19-21 Orlando, FL
CPhI North America
April 24-26 Philadelphia, PA 
April 17-19 New York City
RDD (Respiratory Drug Delivery)
April 22-26 Tucson, AZ
BIO 2018
June 4-7 Boston, MA
Controlled Release Society Meeting
July 23-25 New York City
Universe of Prefilled Syringes & Injection Devices
October 8-9 Orlando, FL

Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions